Opportunity Information: Apply for PA 07 365
Apply for PA 07 365
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Medications Development for the Treatment of Cannabis Related Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 25, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses State governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Public housing authorities/Indian housing authorities Special district governments Small businesses County governments Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Medications Development for the Treatment of Cannabis Related Disorders (R01) opportunity (Funding Opportunity Number PA-07-365) is a National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) funding announcement that supports research aimed at developing safe and effective medications for cannabis-related clinical conditions. The central focus is on moving the field toward pharmacological treatments where none are currently established, addressing a gap NIDA highlights as especially urgent given the high prevalence of cannabis use and a growing public perception that marijuana carries relatively low health risk. The grant is structured to support substantial, hypothesis-driven projects that can advance medication discovery and development through both preclinical and clinical research.
From a scientific scope standpoint, the FOA targets “Cannabis Related Disorders” (CRDs), which includes several categories of problems linked to cannabis use. These include Cannabis Use Disorders (CUDs), such as cannabis abuse and dependence, as well as Cannabis Induced Disorders (CIDs), which can involve acute or longer-lasting effects like intoxication, psychosis, and anxiety. The announcement also explicitly welcomes work that examines cannabis-related conditions in the context of comorbid medical or psychiatric disorders, such as depression, recognizing that cannabis problems frequently overlap with other clinical issues and that treatment strategies may need to account for these interactions. Cannabis is defined broadly to include marijuana, hashish, and other tetrahydrocannabinol (THC)-containing substances.
The mechanism used is the NIH Research Project Grant (R01), which is intended for larger, more comprehensive projects compared to exploratory mechanisms. NIDA notes that this FOA runs in parallel with an announcement of identical scientific scope using the R21 mechanism (PA-07-366), giving investigators an option depending on project maturity and scope. Projects supported under the R01 mechanism can include both new applications and competing renewals, meaning established projects can apply to continue and expand prior work through additional project periods if they compete successfully.
Funding availability and the number of awards are not fixed; awards depend on congressional appropriations, NIDA’s available funds, and the volume and quality of applications received. In other words, it is a competitive, merit-reviewed opportunity where strong scientific justification and feasibility are critical, and the agency does not commit to a guaranteed number of awards.
Eligibility is broad and includes a wide range of U.S. and non-U.S. organizations. Eligible applicants include public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), small businesses and other for-profit organizations (other than small businesses), and multiple levels of government entities (state governments, U.S. territories or possessions, and various local government bodies such as counties, cities/townships, independent school districts, and special district governments). Tribal entities are also eligible, including federally recognized tribes, non-federally recognized tribal governments, and tribally designated organizations. The FOA also lists regional organizations, public housing authorities/Indian housing authorities, and other eligible federal agencies. Foreign (non-U.S.) organizations are explicitly eligible to apply, and the announcement also clarifies that faith-based and community-based organizations may apply. The FOA reflects NIH’s general emphasis on broad participation by encouraging qualified investigators from underrepresented racial and ethnic groups and individuals with disabilities to serve as Project Directors/Principal Investigators (PDs/PIs).
In terms of application logistics and submission rules, applicants are allowed to submit more than one application as long as each proposed project is scientifically distinct. The FOA permits competing renewals, allowing funded projects to seek additional support for subsequent periods through the standard competitive process. Resubmissions are also allowed, but they must include an introduction that directly addresses the issues raised in the prior peer review critique, as documented in the Summary Statement.
Administratively, the opportunity is categorized as a discretionary grant under the NIH, with the CFDA listing 93.279 (Drug Abuse and Addiction Research Programs). It does not require cost sharing or matching funds. The FOA was posted on April 25, 2007, and uses multiple receipt dates (applicants must consult the full announcement for the schedule and due dates). The archived date listed is June 7, 2010, indicating the original FOA is no longer active as a current competition, though it remains an important reference point for how NIDA framed medication development priorities for cannabis-related disorders during that period.
The full announcement is linked through NIH at http://grants.nih.gov/grants/guide/pa-files/PA-07-365.html, and NIH provides an Office of Extramural Research (OER) contact for technical issues accessing the posting (FBOWebmaster@od.nih.gov).
Frequently Asked Questions (FAQs)
What is the Medications Development for the Treatment of Cannabis Related Disorders (R01) opportunity?
It is a National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) funding announcement that supports research to develop safe and effective medications for cannabis-related clinical conditions. The announcement is identified as Funding Opportunity Number (FON) PA-07-365 and uses the NIH Research Project Grant (R01) mechanism.
What is the main goal of this funding opportunity?
The central goal is to move the field toward pharmacological treatments for cannabis-related disorders where no established medications currently exist. The FOA frames this as an urgent gap given the high prevalence of cannabis use and a growing perception that marijuana has relatively low health risk.
What types of research does the R01 mechanism support under this FOA?
The FOA supports substantial, hypothesis-driven projects that can advance medication discovery and development. It allows work spanning both preclinical and clinical research, as long as the focus is aligned with developing medications for cannabis-related clinical conditions.
What conditions are included under “Cannabis Related Disorders (CRDs)” in this announcement?
CRDs include multiple categories of problems linked to cannabis use, including:
- Cannabis Use Disorders (CUDs), such as cannabis abuse and dependence
- Cannabis Induced Disorders (CIDs), which can include acute or longer-lasting effects such as intoxication, psychosis, and anxiety
Does the FOA allow research on comorbid conditions (medical or psychiatric) alongside cannabis-related disorders?
Yes. The announcement explicitly welcomes work examining cannabis-related conditions in the context of comorbid medical or psychiatric disorders (for example, depression). It highlights that cannabis problems often overlap with other clinical issues and that treatment strategies may need to account for these interactions.
How does the FOA define “cannabis” for purposes of this research?
The FOA defines cannabis broadly to include marijuana, hashish, and other tetrahydrocannabinol (THC)-containing substances.
What grant mechanism is used, and what does that imply about project size or scope?
The mechanism is the NIH Research Project Grant (R01). The FOA characterizes this as intended for larger, more comprehensive projects (compared to exploratory mechanisms), supporting substantial hypothesis-driven research programs.
Is there a related opportunity with the same scientific scope but a different mechanism?
Yes. NIDA notes this FOA runs in parallel with an announcement of identical scientific scope using the R21 mechanism (PA-07-366), giving investigators an option depending on project maturity and scope.
Are new applications and renewals allowed under this FOA?
Yes. The FOA allows both new applications and competing renewals. Competing renewals allow previously funded projects to seek additional support for subsequent periods through the standard competitive process.
Can an organization submit more than one application?
Yes. Applicants may submit more than one application as long as each proposed project is scientifically distinct.
Are resubmissions permitted, and is anything special required for a resubmission?
Yes, resubmissions are allowed. The FOA states that resubmissions must include an introduction that directly addresses issues raised in the prior peer review critique, as documented in the Summary Statement.
Is the number of awards or amount of available funding guaranteed?
No. Funding availability and the number of awards are not fixed. Awards depend on congressional appropriations, NIDA’s available funds, and the volume and quality of applications received. The FOA is competitive and merit-reviewed.
Is cost sharing or matching required?
No. The FOA states that it does not require cost sharing or matching funds.
Who is eligible to apply?
Eligibility is broad and includes a wide range of U.S. and non-U.S. organizations. The FOA lists eligible applicants such as:
- Public and private institutions of higher education
- Nonprofits (with or without 501(c)(3) status)
- Small businesses
- Other for-profit organizations (other than small businesses)
- State governments
- U.S. territories or possessions
- Local governments (including counties, cities/townships, independent school districts, and special district governments)
- Tribal entities (federally recognized tribes, non-federally recognized tribal governments, and tribally designated organizations)
- Regional organizations
- Public housing authorities/Indian housing authorities
- Other eligible federal agencies
- Foreign (non-U.S.) organizations
- Faith-based and community-based organizations
Are foreign (non-U.S.) organizations allowed to apply?
Yes. The FOA explicitly states that foreign (non-U.S.) organizations are eligible to apply.
Does the FOA encourage participation by specific groups of investigators?
Yes. Consistent with NIH emphasis on broad participation, the FOA encourages qualified investigators from underrepresented racial and ethnic groups and individuals with disabilities to serve as Project Directors/Principal Investigators (PDs/PIs).
What agency is sponsoring this opportunity and what is the general program area?
The sponsor is the National Institute on Drug Abuse (NIDA) within the National Institutes of Health (NIH). The FOA is associated with CFDA 93.279 (Drug Abuse and Addiction Research Programs).
When was this FOA posted, and is it still active?
The FOA was posted on April 25, 2007. The archived date is listed as June 7, 2010, indicating the original FOA is no longer active as a current competition, though it remains available as a reference.
How are application due dates handled for this FOA?
The FOA uses multiple receipt dates, and applicants are expected to consult the full announcement for the specific schedule and due dates.
Where can applicants find the full announcement text?
The full announcement is available through NIH at: http://grants.nih.gov/grants/guide/pa-files/PA-07-365.html
Who should be contacted for technical issues accessing the NIH posting?
NIH provides an Office of Extramural Research (OER) contact for technical issues accessing the posting: FBOWebmaster@od.nih.gov.
Browse more opportunities from the same category: Education Health
Next opportunity: Medications Development for the Treatment of Cannabis Related Disorders (R21)
Previous opportunity: Grants for Basic Research in Glomerular Diseases (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 365
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 365) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medications Development for the Treatment of Cannabis Related Disorders (R21) Apply for PA 07 366 Funding Number: PA 07 366 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Omics and Variable Responses to CAM Secondary Analysis of CAM Clinical Trials (R01) Apply for PAR 07 377 Funding Number: PAR 07 377 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Omics and Variable Responses to CAM Secondary Analysis of CAM Clinical Trials (R21) Apply for PAR 07 378 Funding Number: PAR 07 378 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Nutrition and Alcohol Related Health Outcomes (R01) Apply for PA 07 403 Funding Number: PA 07 403 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Nutrition and Alcohol Related Health Outcomes (R03) Apply for PA 07 404 Funding Number: PA 07 404 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Genetic Epidemiology of Substance Use Disorders(R01) Apply for PA 07 413 Funding Number: PA 07 413 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Genetic Epidemiology of Substance Use Disorders (R03) Apply for PA 07 414 Funding Number: PA 07 414 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Genetic Epidemiology of Substance Use Disorders(R21) Apply for PA 07 415 Funding Number: PA 07 415 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 07 421 Funding Number: PA 07 421 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R01) Apply for PA 07 422 Funding Number: PA 07 422 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Malignancies in the Context of HIV/AIDS (R21) Apply for PA 07 454 Funding Number: PA 07 454 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research on Malignancies in the Context of HIV/AIDS (R01) Apply for PA 07 455 Funding Number: PA 07 455 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Continued Development and Maintenance of Software (R01) Apply for PAR 08 010 Funding Number: PAR 08 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Angiogenesis in the Nervous System in Health and Disease (R01) Apply for PA 08 015 Funding Number: PA 08 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Angiogenesis in the Nervous System in Health and Disease (R21) Apply for PA 08 016 Funding Number: PA 08 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Quick Trials for Novel Cancer Therapies and Prevention Exploratory Grants (R21) Apply for PAR 08 025 Funding Number: PAR 08 025 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Research on Co Morbid Mental and Other Physical Disorders (R01) Apply for PA 08 029 Funding Number: PA 08 029 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exfoliated Cells, Bioactive Food Components, and Cancer (R01) Apply for PA 08 030 Funding Number: PA 08 030 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exfoliated Cells, Bioactive Food Components, and Cancer (R21) Apply for PA 08 031 Funding Number: PA 08 031 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Molecular Approaches to Diet and Pancreatic Cancer Prevention (R01) Apply for PA 08 032 Funding Number: PA 08 032 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 365", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.